Skip to main content

Table 3 Incidence rates of health outcomes of interest among advanced stage ovarian cancer patients

From: A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer

Health outcome of interest

After advanced stage date (n=12,659)

After anti-cancer therapy date (n=7,723)

Events

Person-years

IRa

95% CI

Events

Person-years

IR

95% CI

Serious infectionb

6662

25868

25.78

25.17

26.41

5,862

15938

41.42

40.36

42.49

Rash

 Any rash

686

22684

3.02

2.8

3.26

431

14095

3.06

2.78

3.36

 Severe cutaneous rash safety events

87

25534

0.34

0.27

0.42

62

15752

0.39

0.3

0.5

Colitis

725

23251

3.12

2.9

3.35

464

14567

3.19

2.91

3.49

Pneumonitis

 Interstitial lung disease

119

25622

0.46

0.39

0.55

62

15812

0.39

0.3

0.5

 Hypersensitivity pneumonitis

≤10

n/a

0.03

0.02

0.06

≤10

n/a

0.03

0.01

0.06

 Pneumonitis or acute interstitial pneumonitis

137

25653

0.53

0.45

0.63

83

15824

0.52

0.42

0.65

Hepatitis

 Hepatic failure

764

23057

3.31

3.08

3.55

510

14112

3.61

3.31

3.94

 Autoimmune hepatitis

≤10

n/a

0.02

0.01

0.05

≤10

n/a

0.03

0.01

0.07

 Hepatitis (not specified as viral)

66

25559

0.26

0.2

0.33

23

15798

0.15

0.09

0.21

 Liver disorder

1439

21567

6.67

6.33

7.02

960

13128

7.31

6.86

7.79

 Transaminases increased

272

25086

1.08

0.96

1.22

169

15483

1.09

0.94

1.27

Nephritis

1966

21201

9.27

8.87

9.69

1,309

13361

9.80

9.28

10.34

Renal failure

2057

21425

9.60

9.19

10.02

1,379

13524

10.20

9.67

10.75

Endocrinopathies

 Adrenal insufficiency

87

25608

0.34

0.27

0.42

44

15839

0.28

0.2

0.37

 Acute and chronic thyroiditis

88

25310

0.35

0.28

0.43

45

15665

0.29

0.21

0.38

 Diabetes mellitus, type 1

124

24894

0.50

0.42

0.59

65

15482

0.42

0.33

0.53

 Diabetic ketoacidosis

40

25745

0.16

0.11

0.21

20

15891

0.13

0.08

0.19

 Hypogonadism

≤10

n/a

0.02

0.01

0.05

≤10

n/a

0.01

0

0.03

 Hypophysitis or hypopituitarism

90

25653

0.35

0.28

0.43

49

15826

0.31

0.23

0.41

 Hypothyroidism

636

18796

3.38

3.13

3.65

325

12002

2.71

2.43

3.01

 Thyroid hyperfunction disorders

121

25084

0.48

0.4

0.57

59

15554

0.38

0.29

0.49

Other safety events

 Abdominal pain

1825

5206

35.06

33.48

36.69

859

3098

27.73

25.92

29.63

 Anemia

2925

11827

24.73

23.85

25.64

1,978

7576

26.11

24.98

27.28

 Anorexia

649

24889

2.61

2.41

2.81

469

15316

3.06

2.79

3.35

 Autoimmune disorder

182

25347

0.72

0.62

0.83

135

15657

0.86

0.73

1.02

 Backache

1632

20754

7.86

7.49

8.25

963

13124

7.34

6.89

7.81

 Constipation

2086

18379

11.35

10.87

11.85

1,404

11460

12.25

11.62

12.91

 Cough

1421

19219

7.39

7.02

7.79

848

12341

6.87

6.42

7.35

 Diarrhea

1502

20365

7.38

7.01

7.76

1,028

12630

8.14

7.65

8.65

 Disorders of bilirubin excretion

66

25798

0.26

0.2

0.32

52

15904

0.33

0.25

0.43

 Disorders of phosphorus metabolism

294

25265

1.16

1.04

1.3

177

15637

1.13

0.97

1.31

 Dizziness and giddiness

977

21121

4.63

4.34

4.92

604

13504

4.47

4.13

4.84

 Edema

1773

20466

8.66

8.27

9.07

1,107

12978

8.53

8.04

9.04

 Encephalitis

18

25811

0.07

0.04

0.11

13

15904

0.08

0.05

0.14

 Fever

1848

20676

8.94

8.54

9.35

1,313

12860

10.21

9.67

10.77

 Guillain-Barre Syndrome

≤10

n/a

0.02

0.01

0.05

≤10

n/a

0.03

0.01

0.06

 Hypertension

1243

10422

11.93

11.28

12.6

775

6820

11.36

10.58

12.18

 Hypopotassemia

1808

20815

8.69

8.29

9.09

1,211

12983

9.33

8.81

9.86

 Hyposmolality and/or hyponatremia

1475

23036

6.40

6.08

6.74

965

14302

6.75

6.33

7.18

 Hypoxemia

1034

23624

4.38

4.12

4.65

590

14805

3.99

3.67

4.32

 Iritis

36

25653

0.14

0.1

0.19

13

15839

0.08

0.05

0.14

 Leukocytosis

1280

23275

5.50

5.2

5.81

792

14379

5.51

5.13

5.9

 Localized superficial swelling, mass, or lump

385

25036

1.54

1.39

1.7

240

15436

1.55

1.37

1.76

 Lymphocytopenia

17

25841

0.07

0.04

0.1

12

15926

0.08

0.04

0.13

 Malaise and fatigue

2945

14296

20.60

19.87

21.35

2,089

9143

22.85

21.88

23.84

 Myasthenia gravis

≤10

n/a

0.03

0.01

0.05

≤10

n/a

0.02

0.01

0.05

 Myocarditis

≤10

n/a

0.01

0

0.02

≤10

n/a

0.01

0

0.04

 Myositis

352

22731

1.55

1.39

1.72

192

14275

1.34

1.16

1.55

 Nausea and vomiting

3436

13816

24.87

24.05

25.71

2,615

8033

32.55

31.32

33.82

 Pain in joint

1584

14017

11.30

10.75

11.87

930

9254

10.05

9.42

10.71

 Pain in limb

1741

16749

10.39

9.91

10.89

1,048

10874

9.64

9.07

10.24

 Pancreatitis (acute or autoimmune)

146

25386

0.58

0.49

0.67

82

15678

0.52

0.42

0.65

 Psoriasis

59

25370

0.23

0.18

0.3

30

15634

0.19

0.13

0.27

 Respiratory abnormalities

≤10

n/a

0.01

0

0.02

≤10

n/a

0.01

0

0.03

 Rheumatoid Arthritis

130

24912

0.52

0.44

0.62

70

15387

0.45

0.36

0.57

 Sarcoidosis

32

25689

0.12

0.09

0.17

≤10

n/a

0.06

0.03

0.1

 Systemic inflammatory response syndrome

116

25634

0.45

0.38

0.54

82

15789

0.52

0.42

0.64

 Thrombocytopenia

1389

23210

5.98

5.68

6.31

1,181

13985

8.44

7.97

8.94

 Uveitis

≤10

n/a

0.00

0

0.02

0

15938

0.00

0

0.02

 Vitiligo

≤10

n/a

0.03

0.01

0.05

≤10

n/a

0.04

0.02

0.08

Overall Mortality

3051

18414

16.57

15.99

17.16

1903

8731

21.80

20.83

22.79

  1. Abbreviations: CI Confidence interval, IR Incidence rate
  2. aEstimates of IR are shown per 100 person-years. Incidence is calculated as the number of new events divided by the sum of person-time at risk, defined as the time between the start of follow-up and the date of the event. In each row, individuals who had a diagnosis of the applicable event prior to the start of follow-up (i.e., prevalent cases) were not included.
  3. bBecause serious infections were defined based on the need for acute care, all events occurred in hospital or emergency room settings.
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us